The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $39.68 up 2.11% from its previous closing price of $38.86. In other words, the price has increased by $2.11 from its previous closing price. On the day, 0.82 million shares were traded. RARE stock price reached its highest trading level at $40.15 during the session, while it also had its lowest trading level at $38.695.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.37. In the meantime, Its Debt-to-Equity ratio is 3.56 whereas as Long-Term Debt/Eq ratio is at 3.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 06 ’25 when Horn Howard sold 1,785 shares for $40.40 per share. The transaction valued at 72,114 led to the insider holds 106,169 shares of the business.
Kassberg Thomas Richard sold 6,028 shares of RARE for $253,779 on Mar 03 ’25. The CBO & EVP now owns 265,238 shares after completing the transaction at $42.10 per share. On Mar 03 ’25, another insider, Parschauer Karah Herdman, who serves as the EVP and Chief Legal Officer of the company, sold 12,846 shares for $42.10 each. As a result, the insider received 540,817 and left with 75,287 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3670443776 and an Enterprise Value of 3977429760. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.55 while its Price-to-Book (P/B) ratio in mrq is 14.36. Its current Enterprise Value per Revenue stands at 7.1 whereas that against EBITDA is -7.948.
Stock Price History:
The Beta on a monthly basis for RARE is 0.57, which has changed by -0.14941049 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -5.81%, while the 200-Day Moving Average is calculated to be -15.92%.
Shares Statistics:
For the past three months, RARE has traded an average of 834.49K shares per day and 683310 over the past ten days. A total of 92.41M shares are outstanding, with a floating share count of 86.26M. Insiders hold about 6.75% of the company’s shares, while institutions hold 95.06% stake in the company. Shares short for RARE as of 1740700800 were 4587206 with a Short Ratio of 5.50, compared to 1738281600 on 4164361. Therefore, it implies a Short% of Shares Outstanding of 4587206 and a Short% of Float of 5.6900002.
Earnings Estimates
The market rating of Ultragenyx Pharmaceutical Inc (RARE) is currently shaped by the ongoing analysis conducted by 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.03 and low estimates of -$1.6.
Analysts are recommending an EPS of between -$3.9 and -$6.42 for the fiscal current year, implying an average EPS of -$5.43. EPS for the following year is -$3.6, with 11.0 analysts recommending between -$0.22 and -$5.01.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $145.92M this quarter.It ranges from a high estimate of $165.4M to a low estimate of $127M. As of the current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $108.83MFor the next quarter, 17 analysts are estimating revenue of $163.04M. There is a high estimate of $174.7M for the next quarter, whereas the lowest estimate is $153M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $673M, while the lowest revenue estimate was $636.6M, resulting in an average revenue estimate of $656.56M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $847.26M in the next fiscal year. The high estimate is $1.02B and the low estimate is $709.7M.
